DENVER, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it has partnered with ProPharma Group, the leading provider of regulatory and compliance services to the pharmaceutical, biotech, and medical device industries.
The United Kingdom has approved trials by London-based Small Pharma for assessing the safety, and later efficacy, of N,N-dimethyltryptamine – or DMT – for depression, according to a Pharm Exec report. It is the world’s first clinical trial for studying DMT as a depression treatment.
MindMed announces a successful pre-Investigational New Drug meeting with the FDA regarding its Project Lucy (LSD) research for anxiety.
They’ve been credited in part for the musical and artistic revolutions of the late 1960s. According to some scientific opinions, they have potentially inspired early creativity in humans and our ancient ancestors.
MindMed's recent financing has closed after being upsized all the way to CAD$34.5 million.
Leading psychedelic stocks have gone ballistic in recent weeks. But where will investors find the NEXT multi-bagger opportunity?
The company is set to open a therapeutic health and training center in Kelowna, British Columbia in May of 2021
Entheon has secured a supply of DMT for delivery to its drug research center (CHDR) in the Netherlands.
Warning: This is probably not for you.
Champignon Brands names an interim CFO after Stephen Brohman resigns.
Mind Cure's initial R&D focus will be on psilocybin, ketamine and ibogaine. Researching both pain and mental health applications for psychedelics.
Mydecine completes its first commercial harvest of 20 kilograms of psilocybin mushrooms.
